Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440001 | 0.90 | CRBN (1.00) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL501751 | 0.90 | CRBN (1.00) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL20234431 | 0.90 | CRBN (1.00) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL4307572 | 0.88 | CRBN (0.78) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL4307848 | 0.88 | CRBN (0.78) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL4307568 | 0.88 | CRBN (0.78) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL24186805 | 0.86 | CRBN (0.75) | CRBN | |
| SCHEMBL22703755 | 0.85 | CRBN (0.73) | CRBN | |
| SCHEMBL21855270 | 0.85 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL22703748 | 0.85 | CRBN (0.73) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038448-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | CELGENE CORPORATION | 2016-04-07 | — | — | US | claimed |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2014-07-03 | — | — | US | claimed |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2013-01-31 | — | — | US | claimed |
| EP-2070920-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080161360-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes | CELGENE CORPORATION | 2008-07-03 | — | — | US | claimed |
| EP-1551953-A4 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORP (US) | 2007-07-18 | — | — | EP | claimed |
| JP-2007513164-A | — | — | 2007-05-24 | — | — | JP | claimed |
| CN-1913896-A | Methods and compositions for the treatment and management of hemoglobinopathies and anemia | CELGENE CORP (US) | 2007-02-14 | — | — | CN | claimed |
| WO-2003087392-A9 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORP (US) | 2004-12-29 | — | — | WO | claimed |
| US-20030235909-A1 | Embryo cells from placenta | ANTHROGENESIS CORPORATION | 2003-12-25 | — | — | US | claimed |
| WO-2003087392-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030144325-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2003-07-31 | — | — | US | claimed |
| EP-0925294-B1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | claimed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | claimed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | claimed |
| US-5635517-A | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | CELGENE CORPORATION (US) | 1997-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030235909-A1 | Embryo cells from placenta | PGF, ALPP, PROX1 | CRBN 2453/4885DDB1 2620/4885BRD4 2500/4885 |
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | TNF, NFKBIA, TRAF2 | CRBN 3501/4885DDB1 447/4885BRD4 1801/4885 |
| US-20030144325-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, INA, VIP | CRBN 4462/4885DDB1 3090/4885BRD4 1758/4885 |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | CRBN 3501/4885DDB1 447/4885BRD4 1801/4885 |
| US-20080161360-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes | IL2, MCL1, MYD88 | CRBN 1257/4885DDB1 1332/4885BRD4 2554/4885 |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, TRAF2 | CRBN 3437/4885DDB1 1125/4885BRD4 1294/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | CRBN 4469/4885DDB1 3697/4885BRD4 1794/4885 |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | CRBN 3601/4885DDB1 396/4885BRD4 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.